Your browser doesn't support javascript.
loading
[Usefulness of GH and IGF-1 to establish the dose and frequency of application of octreotide to treat acromegaly]. / IGF-1 y hormona de crecimiento. Marcadores para la aplicación de octreótida en acromegalia.
Martínez-Delgado, Ignacio Alejandro; Gómez-Martínez, Graciela.
Afiliação
  • Martínez-Delgado IA; Dirección de Educación e Investigación en Salud, Unidad Médica de Alta Especialidad, Hospital de Cardiología 34, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, Mexico. ignacio.martinez@imss.gob.mx
Rev Med Inst Mex Seguro Soc ; 45(3): 291-5, 2007.
Article em Es | MEDLINE | ID: mdl-17692168
OBJECTIVE: to determine the dose and frequency of application of octreotide LAR to treat acromegaly by monitoring the levels of circulating growth hormone (GH) and insulin-like growth factor (IGF-1). MATERIAL AND METHODS: twelve patients (five men and seven women) with acromegaly, whose age was on average 48.9 years (range 35-67) participated. Eight had been surgically treated, yet non cured and 4 patients were treated de novo. The study lasted between 12-18 months. The initial octreotide dose was 20 mg/4 weeks intramuscular. Before administering the fourth dose, the levels of IGF-1 and GH were measured; then, the dose was adjusted and three more injections were applied. If the levels of GH and IGF-1 continued safe, the dose and frequency of application of octreotide LAR were individualized thus applying the minimum number of injections. RESULTS: the interval of octreotide LAR application to maintain the levels of GH and IGF-1 within safe range was prolonged to more than four weeks in nine patients (75%); in six patients (50%), the interval changed to eight weeks and to twelve weeks in three patients (25%). Three patients (25%) continued receiving injections in four-week intervals. The levels of GH and IGF-1 were lower during the treatment period when compared with the baseline measurements (p < 0.01). CONCLUSION: the adjustment of the dose of octreotide LAR keeps the levels of GH within safe range and reduces in 75% the frequency of injections to treat acromegaly.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acromegalia / Fator de Crescimento Insulin-Like I / Hormônio do Crescimento / Octreotida Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Es Revista: Rev Med Inst Mex Seguro Soc Assunto da revista: MEDICINA / MEDICINA SOCIAL Ano de publicação: 2007 Tipo de documento: Article País de afiliação: México País de publicação: México
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acromegalia / Fator de Crescimento Insulin-Like I / Hormônio do Crescimento / Octreotida Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Es Revista: Rev Med Inst Mex Seguro Soc Assunto da revista: MEDICINA / MEDICINA SOCIAL Ano de publicação: 2007 Tipo de documento: Article País de afiliação: México País de publicação: México